secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0001641172-25-000199
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA Pharma to acquire SKNY in stock-for-stock deal; adds weight loss drug SKNY-1
--------------------------------------------------------------------------------

- SKNY contributes $5M in cash/assets at closing, no contingencies.
- Exchange ratio determined by independent valuation; subject to SKNY valuation >= MIRA market value.
- 90-day mutual due diligence period; definitive agreement required within 180 days after.
- No SKNY board, executives, or employees will retain roles post-closing.
- SKNY stockholders subject to 6-month lock-up on MIRA shares received.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225000199/0001641172-25-000199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225000199/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-000199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer